Why the study?
Superior vena cava syndrome is a rare but serious complication after pacemaker lead implantation, with benign iatrogenic causes becoming increasingly common.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Direct oral anticoagulation with edoxaban may be an effective and non-invasive treatment option for superior vena cava syndrome complicating pacemaker implantation.
BACKGROUND: Superior Vena Cava (SVC) syndrome, is a quite rare but serious complication after pacemaker lead implantation; most patients are asymptomatic due to the development of adequate venous collateral circulation. CASE PRESENTATION: We report a case of a 75-year-old woman who developed SVC syndrome after transvenous pacemaker implantation with complete resolution of the thrombosis after 3 months of oral anticoagulation. CONCLUSIONS: Generally other causes as malignancy are considered to be the most common etiology of SVC syndrome, but benign iatrogenic causes, mainly intravascular devices (central vein catheters, cardiac defibrillators and pacemaker wires), are becoming increasingly common. Procedures performed on venous vasculature, causing a possible intimal injury or vein stenosis, provoked by transvenous leads, seem to be the most reasonable explanation for the observed complication.
No takes yet. Share an insight, caveat, or question.
Mumoli et al. (2021) conducted a case report in Superior Vena Cava (SVC) syndrome (n=1). Edoxaban was evaluated on Resolution of thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: